{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:06:56Z","timestamp":1791893216664,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejca.2025.115670","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:14:27Z","timestamp":1753888467000},"page":"115670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient biliary tract cancer: An AGEO study"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1259-7890","authenticated-orcid":false,"given":"Iona","family":"Campo-Le-Brun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Grapinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Aurillac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Parent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Girot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-9635","authenticated-orcid":false,"given":"David","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Gendreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4688-8765","authenticated-orcid":false,"given":"Brice","family":"Chanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Assenat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4580-585X","authenticated-orcid":false,"given":"Simon","family":"Pernot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Alouani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1649-9577","authenticated-orcid":false,"given":"Sahir","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8421-3182","authenticated-orcid":false,"given":"Yann","family":"Touchefeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gael","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6412-932X","authenticated-orcid":false,"given":"Marie","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Bachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Lequoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-6448","authenticated-orcid":false,"given":"Vincent","family":"Hautefeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher","family":"Ben-Abdelghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosine","family":"Guimbaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Boil\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-2106","authenticated-orcid":false,"given":"Marie","family":"Decraecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2025.115670_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115670_bib2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2025.115670_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma \u2014 evolving concepts and therapeutic strategies","volume":"15","author":"Ilyas","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"S1","key":"10.1016\/j.ejca.2025.115670_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.ejca.2025.115670_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the european network for the study of cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115670_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115670_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2012.02.022","article-title":"Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma","volume":"57","author":"Palmer","year":"2012","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.ejca.2025.115670_bib8","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3390\/cancers13071569","article-title":"Immunotherapy in advanced biliary tract cancers","volume":"13","author":"Boil\u00e8ve","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.ejca.2025.115670_bib9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115670_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41416-018-0199-2","article-title":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","volume":"120","author":"Goeppert","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2025.115670_bib11","doi-asserted-by":"crossref","unstructured":"Oh D.Y., Ruth He A., Qin S., Chen L.T., Okusaka T., Vogel A., et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid [Internet]. 2022 [Accessed 23 June 2024];1(8). Available from: \u3008https:\/\/evidence.nejm.org\/doi\/10.1056\/EVIDoa2200015\u3009.","DOI":"10.1056\/EVIDoa2200015"},{"issue":"1","key":"10.1016\/j.ejca.2025.115670_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12916-024-03257-7","article-title":"Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma","volume":"22","author":"Yang","year":"2024","journal-title":"BMC Med"},{"issue":"10391","key":"10.1016\/j.ejca.2025.115670_bib13","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2025.115670_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability\/Mismatch Repair\u2013Deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115670_bib15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s43018-024-00894-y","article-title":"Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial","volume":"6","author":"Marabelle","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejca.2025.115670_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114033","article-title":"A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability","volume":"202","author":"Moreau","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115670_bib17","unstructured":"btc.pdf [Internet]. [Accessed 8 December 2024]. 2024. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/btc.pdf."},{"issue":"5","key":"10.1016\/j.ejca.2025.115670_bib18","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3390\/ijms19051421","article-title":"Microsatellite instability occurs rarely in patients with cholangiocarcinoma: a retrospective study from a German tertiary care hospital","volume":"19","author":"Winkelmann","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.ejca.2025.115670_bib19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.21037\/cco.2016.10.04","article-title":"Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency","volume":"5","author":"Silva","year":"2016","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115670_bib20","doi-asserted-by":"crossref","first-page":"S1462","DOI":"10.1016\/j.annonc.2022.10.114","article-title":"78P updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)","volume":"33","author":"Oh","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115670_bib21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115670_bib22","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3390\/jcm9092854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.ejca.2025.115670_bib23","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.115670_bib24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision Medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur J Cancer"},{"issue":"18","key":"10.1016\/j.ejca.2025.115670_bib25","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.3390\/cancers15184446","article-title":"Targetable molecular alterations in the treatment of biliary tract cancers: an overview of the available treatments","volume":"15","author":"Valery","year":"2023","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.ejca.2025.115670_bib26","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"6349","key":"10.1016\/j.ejca.2025.115670_bib27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.ejca.2025.115670_bib28","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2025.115670_bib29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jcmgh.2023.12.010","article-title":"Germline genetic associations for hepatobiliary cancers","volume":"17","author":"Chotiprasidhi","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925004526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925004526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T13:37:15Z","timestamp":1771940235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925004526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":29,"alternative-id":["S0959804925004526"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115670","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient biliary tract cancer: An AGEO study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115670"}}